Prelude Therapeutics Q3 net loss $32.3M; PRT3789 shows partial responses in SMARCA4-mutated cancers

Prelude Therapeutics Inc

2024-Q3 EPS reported -$1.30 revenue$3,000,000

Cash, equivalents and marketable securities $153.6M; net loss $32.3M ($0.43/share) vs $30.6M prior year.
PRT3789 Phase 1: 4 confirmed partial responses in 26 evaluable SMARCA4-mutated NSCLC/esophageal patients; combo with docetaxel safe.
Initiated Phase 1 trial of oral SMARCA2 degrader PRT7732 in biomarker-selected SMARCA4-mutated cancers.
PRT2527 interim Phase 1 data in hematological malignancies to be presented at ASH Dec 2024; dose escalation completing this year.
Entered collaboration with Pfizer Ignite for SMARCA2 degrader development; Prelude retains full ownership.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.